{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:14:19Z","timestamp":1793826859808,"version":"4.6.1"},"reference-count":248,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More recently, ICIs are also being used in the adjuvant setting for high-risk patients. However, treatment with ICIs requires a nuanced understanding of topics such as patient selection, histology and risk considerations, and integration with local therapies. As such, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline (CPG) on immunotherapy for the treatment of RCC. Drawing from published data and clinical experience, the Expert Panel developed evidence-based and consensus-based recommendations. Topics include therapy selection in the adjuvant and metastatic settings, considerations for special patient populations, response monitoring, and patient education and quality of life considerations, among others, with the goal of improving patient care by providing guidance to the oncology community.<\/jats:p>","DOI":"10.1136\/jitc-2025-013788","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:25:20Z","timestamp":1774283120000},"page":"e013788","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02231749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03142334","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03138512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03024996","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03055013","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03288532","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05239728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02853331","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03141177","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02811861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02231749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03977571","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04510597","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04322955","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02853331","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03141177","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02811861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02231749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684006","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02420821","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03937219","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03793166","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03203473","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03117309","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02917772","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04338269","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02596035","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03117309","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02853344","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02982954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03075423","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04704219","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02855203","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rana R","family":"McKay","sequence":"first","affiliation":[{"name":"Departments of Medicine and Urology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Ajmera","sequence":"additional","affiliation":[{"name":"Department Hematology-Oncology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B","family":"Atkins","sequence":"additional","affiliation":[{"name":"Department of Oncology, Georgetown University Medical Center, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C","family":"Barata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Bergerot","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Oncoclinicas and Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic Glickman Urological Institute, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Ari","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Poteat","sequence":"additional","affiliation":[{"name":"KidneyCAN, Beavercreek, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, London, Greater London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shuch","sequence":"additional","affiliation":[{"name":"Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Yip","sequence":"additional","affiliation":[{"name":"Department of Surgery, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-3531","authenticated-orcid":false,"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026090204552123000_14.3.e013788.1","unstructured":"National Cancer Institute . Cancer stat facts: kidney and renal pelvis cancer. 2025 Available: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html"},{"key":"2026090204552123000_14.3.e013788.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026090204552123000_14.3.e013788.3","first-page":"1541","article-title":"Chemotherapy for renal cell carcinoma","volume":"19","author":"Hartmann","year":"1999","journal-title":"Anticancer Res"},{"key":"2026090204552123000_14.3.e013788.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0316-3"},{"key":"2026090204552123000_14.3.e013788.5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semnephrol.2019.12.004","article-title":"The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age","volume":"40","author":"Huang","year":"2020","journal-title":"Semin Nephrol"},{"key":"2026090204552123000_14.3.e013788.6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H"},{"key":"2026090204552123000_14.3.e013788.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"2026090204552123000_14.3.e013788.8","doi-asserted-by":"publisher","DOI":"10.15586\/jkcvhl.2014.7"},{"key":"2026090204552123000_14.3.e013788.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25583"},{"key":"2026090204552123000_14.3.e013788.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"2026090204552123000_14.3.e013788.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"2026090204552123000_14.3.e013788.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2026090204552123000_14.3.e013788.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2026090204552123000_14.3.e013788.14","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on Biomarkers in Renal Cell Carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026090204552123000_14.3.e013788.15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5063","article-title":"Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes","volume":"38","author":"Dudani","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.17","unstructured":"Daniel Heng TC , Xie W . IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma. 2005."},{"key":"2026090204552123000_14.3.e013788.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70559-4"},{"key":"2026090204552123000_14.3.e013788.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.179"},{"key":"2026090204552123000_14.3.e013788.20","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA A Cancer J Clinicians"},{"key":"2026090204552123000_14.3.e013788.21","unstructured":"Edition S , Edge S , Byrd D . AJCC cancer staging manual. 2017."},{"key":"2026090204552123000_14.3.e013788.22","article-title":"A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma","volume":"13","author":"Morshid","year":"2021","journal-title":"Cureus"},{"key":"2026090204552123000_14.3.e013788.23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4103\/1450-1147.150535","article-title":"Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography\/computed tomography in management of renal cell carcinoma: a single institution experience","volume":"14","author":"Win","year":"2015","journal-title":"World J Nucl Med"},{"key":"2026090204552123000_14.3.e013788.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42289","article-title":"FDG-PET Positivity and Overall Survival in Renal Cell Carcinoma","volume":"5","author":"Ferdinandus","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026090204552123000_14.3.e013788.25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2214\/AJR.19.22467","article-title":"FDG PET\/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation","volume":"215","author":"Zhu","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"2026090204552123000_14.3.e013788.26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026090204552123000_14.3.e013788.27","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G"},{"key":"2026090204552123000_14.3.e013788.28","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2013.1927"},{"key":"2026090204552123000_14.3.e013788.29","doi-asserted-by":"crossref","first-page":"S1432","DOI":"10.1016\/j.annonc.2022.08.072","article-title":"LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial","volume":"33","author":"Allaf","year":"2022","journal-title":"Ann Oncol"},{"key":"2026090204552123000_14.3.e013788.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01658-0"},{"key":"2026090204552123000_14.3.e013788.31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","article-title":"Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb\/IV CheckMate 374 Study","volume":"18","author":"Vogelzang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"2026090204552123000_14.3.e013788.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004780","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-na\u00efve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)","volume":"11","author":"Atkins","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.34","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00276-0"},{"key":"2026090204552123000_14.3.e013788.37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.941835","article-title":"The role of immunotherapy in non-clear cell renal cell carcinoma","volume":"13","author":"Climent","year":"2023","journal-title":"Front Oncol"},{"key":"2026090204552123000_14.3.e013788.38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153652","article-title":"Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities","volume":"13","author":"Zarrabi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026090204552123000_14.3.e013788.39","article-title":"The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates","volume":"16","author":"Goswami","year":"2024","journal-title":"Cureus"},{"key":"2026090204552123000_14.3.e013788.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.06.016"},{"key":"2026090204552123000_14.3.e013788.41","unstructured":"Board WCoTE . Urinary and male genital tumours: international agency for research on cancer. 2022."},{"key":"2026090204552123000_14.3.e013788.42","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198210000-00007"},{"key":"2026090204552123000_14.3.e013788.43","doi-asserted-by":"publisher","DOI":"10.1111\/his.13311"},{"key":"2026090204552123000_14.3.e013788.44","doi-asserted-by":"publisher","DOI":"10.1111\/his.13735"},{"key":"2026090204552123000_14.3.e013788.45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00292-016-0171-y","article-title":"The WHO\/ISUP grading system for renal carcinoma","volume":"37","author":"Moch","year":"2016","journal-title":"Pathologe"},{"key":"2026090204552123000_14.3.e013788.46","first-page":"100640","article-title":"The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma","volume":"33","author":"Hahn","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"2026090204552123000_14.3.e013788.47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2063"},{"key":"2026090204552123000_14.3.e013788.48","unstructured":"Food and Drug Administration (FDA) . FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer. FDA gov US Food and Drug Administration; 2017.21."},{"key":"2026090204552123000_14.3.e013788.49","unstructured":"Food and Drug Administration (FDA) . FDA approves pembrolizumab for advanced endometrial carcinoma. Silver Spring, MD, USA FDA; 2022."},{"key":"2026090204552123000_14.3.e013788.50","unstructured":"U.S. Food & Drug Administration . FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2017."},{"key":"2026090204552123000_14.3.e013788.51","unstructured":"Food and Drug Administration (FDA) . FDA approves pembrolizumab for adults and children with TMB-H solid tumors. News release Silver Spring, MD US Food and Drug Administration; 2020."},{"key":"2026090204552123000_14.3.e013788.52","unstructured":"Food and Drug Administration (FDA) . FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. US Food and Drug Administration; 2021."},{"key":"2026090204552123000_14.3.e013788.53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026090204552123000_14.3.e013788.54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071945","article-title":"The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials","volume":"12","author":"Carretero-Gonz\u00e1lez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026090204552123000_14.3.e013788.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1993"},{"key":"2026090204552123000_14.3.e013788.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1044-8"},{"key":"2026090204552123000_14.3.e013788.57","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2026090204552123000_14.3.e013788.58","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213"},{"key":"2026090204552123000_14.3.e013788.59","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2020.02.81","article-title":"Tumor mutational burden and immune signatures interplay in renal cell carcinoma","volume":"8","author":"Yakirevich","year":"2020","journal-title":"Ann Transl Med"},{"key":"2026090204552123000_14.3.e013788.60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4058"},{"key":"2026090204552123000_14.3.e013788.61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"2026090204552123000_14.3.e013788.62","unstructured":"Food and Drug Administration (FDA) Merck . Pembrolizumab (keytruda) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125514"},{"key":"2026090204552123000_14.3.e013788.63","unstructured":"Food and Drug Administration (FDA) GlaxoSmithKline . Dostarlimab (JEMPERLI) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761174"},{"key":"2026090204552123000_14.3.e013788.64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00372","article-title":"Comprehensive Genomic Analysis of Metastatic Non\u2013Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets","volume":"3","author":"Carlo","year":"2019","journal-title":"JCO Precision Oncology"},{"key":"2026090204552123000_14.3.e013788.65","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026090204552123000_14.3.e013788.66","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2025.43.5_suppl.437","article-title":"Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214","volume":"43","author":"Xu","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.67","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2025.43.5_suppl.594","article-title":"KIM-1 as a circulating biomarker in metastatic RCC: Post-hoc analysis of JAVELIN Renal 101","volume":"43","author":"Machaalani","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.007"},{"key":"2026090204552123000_14.3.e013788.69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000319","article-title":"Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma","volume":"8","author":"Labriola","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/CCO.0000000000000518","article-title":"PET imaging in renal cancer","volume":"31","author":"Lindenberg","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2026090204552123000_14.3.e013788.71","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/iju.14816","article-title":"Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"29","author":"Koh","year":"2022","journal-title":"Int J Urol"},{"key":"2026090204552123000_14.3.e013788.72","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1038\/s41598-021-85099-4","article-title":"Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2026090204552123000_14.3.e013788.73","unstructured":"Pandey J , Syed W . Renal cancer. 2020."},{"key":"2026090204552123000_14.3.e013788.74","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.926661","article-title":"Adjuvant therapy for renal cell carcinoma, finally a new standard?","volume":"12","author":"Renner","year":"2022","journal-title":"Front Oncol"},{"key":"2026090204552123000_14.3.e013788.75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611406"},{"key":"2026090204552123000_14.3.e013788.76","unstructured":"Food and Drug Administration (FDA) Pfizer . Sunitinib (sutent) prescribing information 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021938s039lbledt.pdf"},{"key":"2026090204552123000_14.3.e013788.77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00559-6"},{"key":"2026090204552123000_14.3.e013788.78","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1177\/02841851211052999","article-title":"Cross-sectional imaging assessment of renal masses with emphasis on MRI","volume":"63","author":"Tsili","year":"2022","journal-title":"Acta Radiol"},{"key":"2026090204552123000_14.3.e013788.79","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21331"},{"key":"2026090204552123000_14.3.e013788.80","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000165572.38887.da"},{"key":"2026090204552123000_14.3.e013788.81","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-017-0661-3"},{"key":"2026090204552123000_14.3.e013788.82","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.005"},{"key":"2026090204552123000_14.3.e013788.83","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000148261.19532.2c"},{"key":"2026090204552123000_14.3.e013788.84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euo.2020.09.005","article-title":"The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium","volume":"4","author":"Abu-Ghanem","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026090204552123000_14.3.e013788.85","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21681805.2019.1588919","article-title":"Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.)","volume":"53","author":"Dabestani","year":"2019","journal-title":"Scand J Urol"},{"key":"2026090204552123000_14.3.e013788.86","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.euf.2018.02.010","article-title":"Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis","volume":"5","author":"Dabestani","year":"2019","journal-title":"Eur Urol Focus"},{"key":"2026090204552123000_14.3.e013788.87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2018.10.007","article-title":"Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR)","volume":"75","author":"Dabestani","year":"2019","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.025"},{"key":"2026090204552123000_14.3.e013788.89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.104"},{"key":"2026090204552123000_14.3.e013788.90","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/cncr.35037","article-title":"2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race","volume":"130","author":"Schmeusser","year":"2024","journal-title":"Cancer"},{"key":"2026090204552123000_14.3.e013788.91","unstructured":"Food and Drug Administration (FDA) . FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. FDA; 2021. Available: https:\/\/www fda gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma"},{"key":"2026090204552123000_14.3.e013788.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391"},{"key":"2026090204552123000_14.3.e013788.93","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9"},{"key":"2026090204552123000_14.3.e013788.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"2026090204552123000_14.3.e013788.95","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02574-0"},{"key":"2026090204552123000_14.3.e013788.96","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA358","article-title":"Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00211-0"},{"key":"2026090204552123000_14.3.e013788.98","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMe2402364","article-title":"Adjuvant Immunotherapy for Kidney Cancer \u2014 A New Strategy with New Challenges","volume":"390","author":"Voss","year":"2024","journal-title":"N Engl J Med"},{"key":"2026090204552123000_14.3.e013788.99","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41585-022-00666-2","article-title":"Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade","volume":"20","author":"Fitzgerald","year":"2023","journal-title":"Nat Rev Urol"},{"key":"2026090204552123000_14.3.e013788.100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","article-title":"Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results","volume":"73","author":"Motzer","year":"2018","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.101","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.943604","article-title":"Role of metastasectomy in the management of renal cell carcinoma","volume":"9","author":"Mikhail","year":"2022","journal-title":"Front Surg"},{"key":"2026090204552123000_14.3.e013788.102","article-title":"SABR for oligometastatic renal cell carcinoma","volume":"45","author":"David","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026090204552123000_14.3.e013788.103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","article-title":"LITESPARK-022: A phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.104","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2178217"},{"key":"2026090204552123000_14.3.e013788.105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003892","article-title":"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.106","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.2566","article-title":"Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I\/II basket clinical trial\u2014Report after completion of monotherapy dose-finding","volume":"41","author":"Ottensmeier","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.107","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.KIDNEY23-PR015","article-title":"Abstract PR015: Tumor-specific immunity generated by a personalized neoantigen vaccination incorporating locally delivered ipilimumab in renal cell carcinoma","volume":"83","author":"Braun","year":"2023","journal-title":"Cancer Res"},{"key":"2026090204552123000_14.3.e013788.108","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: Dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"Oncoimmunology"},{"key":"2026090204552123000_14.3.e013788.109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4553","article-title":"Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study","volume":"40","author":"Fernandes","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2530"},{"key":"2026090204552123000_14.3.e013788.111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12032-018-1147-y","article-title":"Check point inhibitors a new era in renal cell carcinoma treatment","volume":"35","author":"Alsharedi","year":"2018","journal-title":"Med Oncol"},{"key":"2026090204552123000_14.3.e013788.112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"2026090204552123000_14.3.e013788.113","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0291-1"},{"key":"2026090204552123000_14.3.e013788.114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02218"},{"key":"2026090204552123000_14.3.e013788.115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.289"},{"key":"2026090204552123000_14.3.e013788.116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"2026090204552123000_14.3.e013788.117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803675"},{"key":"2026090204552123000_14.3.e013788.118","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090204552123000_14.3.e013788.119","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.3390\/curroncol28030178","article-title":"Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature","volume":"28","author":"Dawsey","year":"2021","journal-title":"Curr Oncol"},{"key":"2026090204552123000_14.3.e013788.120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-210010","article-title":"\u201cPROBE\u201ding the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer","volume":"6","author":"Bell","year":"2022","journal-title":"Kidney Cancer"},{"key":"2026090204552123000_14.3.e013788.121","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","article-title":"Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial","volume":"24","author":"Iisager","year":"2024","journal-title":"BMC Cancer"},{"key":"2026090204552123000_14.3.e013788.122","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS371","article-title":"Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK)","volume":"39","author":"Runcie","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.123","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/oncolo\/oyad166","article-title":"Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy","volume":"29","author":"Panian","year":"2024","journal-title":"Oncologist"},{"key":"2026090204552123000_14.3.e013788.124","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS761","article-title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab\/nivolumab for metastatic kidney cancer (CYTOSHRINK)","volume":"38","author":"Lalani","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4604","article-title":"NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)","volume":"41","author":"Hall","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.006"},{"key":"2026090204552123000_14.3.e013788.127","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2020.38.15_suppl.5001","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426","volume":"38","author":"Plimack","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.128","unstructured":"Food and Drug Administration (FDA) BMS . Nivolumab (OPDIVO) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125554s127lbl.pdf"},{"key":"2026090204552123000_14.3.e013788.129","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994"},{"key":"2026090204552123000_14.3.e013788.130","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2024.42.16_suppl.4507","article-title":"Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)","volume":"42","author":"Mantia","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.131","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00290-X"},{"key":"2026090204552123000_14.3.e013788.132","unstructured":"Food and Drug Administration (FDA) BMS . Nivolumab and hyaluronidase (OPDIVO QVANTIG) prescribing information. 2024. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761381"},{"key":"2026090204552123000_14.3.e013788.133","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"2026090204552123000_14.3.e013788.134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01569"},{"key":"2026090204552123000_14.3.e013788.135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2024.42.4_suppl.363","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2283"},{"key":"2026090204552123000_14.3.e013788.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"2026090204552123000_14.3.e013788.138","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"key":"2026090204552123000_14.3.e013788.139","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"2026090204552123000_14.3.e013788.140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212851"},{"key":"2026090204552123000_14.3.e013788.141","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2025.43.5_suppl.438","article-title":"Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313","volume":"43","author":"Albiges","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.142","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.206"},{"key":"2026090204552123000_14.3.e013788.143","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23552"},{"key":"2026090204552123000_14.3.e013788.144","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0522-3"},{"key":"2026090204552123000_14.3.e013788.145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS760","article-title":"PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)","volume":"38","author":"Zhang","year":"2020","journal-title":"JCO"},{"key":"2026090204552123000_14.3.e013788.146","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0476"},{"key":"2026090204552123000_14.3.e013788.147","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00922-4"},{"key":"2026090204552123000_14.3.e013788.148","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01758-6"},{"key":"2026090204552123000_14.3.e013788.149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005780","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.150","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijms24021096","article-title":"Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)","volume":"24","author":"Stellato","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026090204552123000_14.3.e013788.151","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2318","article-title":"LBA75 Prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial","volume":"35","author":"Bergmann","year":"2024","journal-title":"Ann Oncol"},{"key":"2026090204552123000_14.3.e013788.152","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4611","article-title":"Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study","volume":"42","author":"Pal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.153","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS493","article-title":"SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC)","volume":"42","author":"Maughan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.154","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4601","article-title":"SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced\/metastatic papillary renal cell carcinoma (PRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.155","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"2026090204552123000_14.3.e013788.156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13643-4"},{"key":"2026090204552123000_14.3.e013788.157","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2010.175"},{"key":"2026090204552123000_14.3.e013788.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.01.005"},{"key":"2026090204552123000_14.3.e013788.159","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0008"},{"key":"2026090204552123000_14.3.e013788.160","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"2026090204552123000_14.3.e013788.161","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy099"},{"key":"2026090204552123000_14.3.e013788.162","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083026","article-title":"Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS ONE"},{"key":"2026090204552123000_14.3.e013788.163","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"2026090204552123000_14.3.e013788.164","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"2026090204552123000_14.3.e013788.165","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390038","article-title":"State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma","volume":"43","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026090204552123000_14.3.e013788.166","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.euo.2018.08.028","article-title":"Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"European Urology Oncology"},{"key":"2026090204552123000_14.3.e013788.167","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma\u2014The RAPPORT Trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.168","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026090204552123000_14.3.e013788.169","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/cancers13071689","article-title":"Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors\u2014Navigating the Radiologic Potpourri","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026090204552123000_14.3.e013788.170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.171","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2026090204552123000_14.3.e013788.172","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026090204552123000_14.3.e013788.173","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"2026090204552123000_14.3.e013788.174","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clgc.2018.07.015","article-title":"Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back","volume":"16","author":"Elias","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"2026090204552123000_14.3.e013788.175","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.640447","article-title":"Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"2026090204552123000_14.3.e013788.176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.07.002"},{"key":"2026090204552123000_14.3.e013788.177","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clgc.2023.03.003","article-title":"Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis","volume":"21","author":"Haaker","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2026090204552123000_14.3.e013788.178","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2016.0775","article-title":"Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial","volume":"2","author":"George","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026090204552123000_14.3.e013788.179","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0895"},{"key":"2026090204552123000_14.3.e013788.181","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1644"},{"key":"2026090204552123000_14.3.e013788.182","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/KCA-229003","article-title":"Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer","volume":"6","author":"Parikh","year":"2022","journal-title":"Kidney Cancer"},{"key":"2026090204552123000_14.3.e013788.183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2026090204552123000_14.3.e013788.184","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33033"},{"key":"2026090204552123000_14.3.e013788.185","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"},{"key":"2026090204552123000_14.3.e013788.186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.187","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026090204552123000_14.3.e013788.188","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0020"},{"key":"2026090204552123000_14.3.e013788.189","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073"},{"key":"2026090204552123000_14.3.e013788.190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008"},{"key":"2026090204552123000_14.3.e013788.191","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000538","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study","volume":"8","author":"Martinez Chanza","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.192","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618"},{"key":"2026090204552123000_14.3.e013788.193","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189"},{"key":"2026090204552123000_14.3.e013788.194","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824645","article-title":"Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma","volume":"9","author":"Drakaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026090204552123000_14.3.e013788.195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026090204552123000_14.3.e013788.196","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2026090204552123000_14.3.e013788.197","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004"},{"key":"2026090204552123000_14.3.e013788.198","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.199","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"key":"2026090204552123000_14.3.e013788.200","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026090204552123000_14.3.e013788.201","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.872438","article-title":"Renal Cell Carcinoma Associated With HIV\/AIDS: A Review of the Epidemiology, Risk Factors, Diagnosis, and Treatment","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol"},{"key":"2026090204552123000_14.3.e013788.202","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090204552123000_14.3.e013788.203","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459"},{"key":"2026090204552123000_14.3.e013788.204","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090204552123000_14.3.e013788.205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.206","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050283"},{"key":"2026090204552123000_14.3.e013788.207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11255-021-03042-y","article-title":"Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma","volume":"54","author":"Nemoto","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2026090204552123000_14.3.e013788.208","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clgc.2019.11.016","article-title":"Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma","volume":"18","author":"Varkaris","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"2026090204552123000_14.3.e013788.209","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2022.40.6_suppl.320","article-title":"Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)","volume":"40","author":"Carril","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.210","doi-asserted-by":"crossref","first-page":"101742","DOI":"10.1016\/j.jgo.2024.101742","article-title":"Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper","volume":"15","author":"Guven","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"2026090204552123000_14.3.e013788.211","doi-asserted-by":"crossref","first-page":"100262","DOI":"10.1016\/j.esmoop.2021.100262","article-title":"Immune checkpoint inhibitor administration during pregnancy: a case series","volume":"6","author":"Andrikopoulou","year":"2021","journal-title":"ESMO Open"},{"key":"2026090204552123000_14.3.e013788.212","unstructured":"Food and Drug Administration (FDA) BMS . Ipilimumab (YERVOY) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125377s129lbl.pdf"},{"key":"2026090204552123000_14.3.e013788.213","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0837"},{"key":"2026090204552123000_14.3.e013788.214","doi-asserted-by":"crossref","first-page":"100276","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"2026090204552123000_14.3.e013788.215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2026090204552123000_14.3.e013788.216","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.217","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0557-5"},{"key":"2026090204552123000_14.3.e013788.218","first-page":"271","article-title":"Immune checkpoint inhibitor therapy","volume":"23","author":"Wood","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2026090204552123000_14.3.e013788.219","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001872","article-title":"Exercise and the immune system: taking steps to improve responses to cancer immunotherapy","volume":"9","author":"Gustafson","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.220","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/OP.2023.19.11_suppl.267","article-title":"Effects of a remote physical activity program on immune-related side effects and quality of life: A Brazilian study","volume":"19","author":"Bergerot","year":"2023","journal-title":"JCO Oncology Practice"},{"key":"2026090204552123000_14.3.e013788.221","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jnci\/djad245","article-title":"Physical activity and checkpoint inhibition: association with toxicity and survival","volume":"116","author":"Verheijden","year":"2024","journal-title":"JNCI"},{"key":"2026090204552123000_14.3.e013788.222","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00687"},{"key":"2026090204552123000_14.3.e013788.223","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.24.00541","article-title":"Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update","volume":"42","author":"Bower","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.224","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(95)70270-9"},{"key":"2026090204552123000_14.3.e013788.225","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015"},{"key":"2026090204552123000_14.3.e013788.226","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01694-6"},{"key":"2026090204552123000_14.3.e013788.227","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00074"},{"key":"2026090204552123000_14.3.e013788.228","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716317","article-title":"Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors","volume":"12","author":"Giordan","year":"2021","journal-title":"Front Immunol"},{"key":"2026090204552123000_14.3.e013788.229","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221111703","article-title":"Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026090204552123000_14.3.e013788.230","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-5-1"},{"key":"2026090204552123000_14.3.e013788.231","unstructured":"EuroQol . EQ-5d website. 2026 Available: https:\/\/euroqol.org"},{"key":"2026090204552123000_14.3.e013788.232","unstructured":"European organization for research and treatment of cancer quality of life group website. n.d. Available: https:\/\/qol.eortc.org"},{"key":"2026090204552123000_14.3.e013788.233","first-page":"191","article-title":"Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"},{"key":"2026090204552123000_14.3.e013788.234","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41591-022-01745-y","article-title":"Suicide risk and mortality among patients with cancer","volume":"28","author":"Heinrich","year":"2022","journal-title":"Nat Med"},{"key":"2026090204552123000_14.3.e013788.235","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41591-022-01763-w","article-title":"Shining a light on the psychological burden of cancer","volume":"28","author":"Bergerot","year":"2022","journal-title":"Nat Med"},{"key":"2026090204552123000_14.3.e013788.236","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3055"},{"key":"2026090204552123000_14.3.e013788.237","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"2026090204552123000_14.3.e013788.238","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(13)62416-2","article-title":"Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial","volume":"383","author":"Zimmermann","year":"2014","journal-title":"The Lancet"},{"key":"2026090204552123000_14.3.e013788.239","doi-asserted-by":"publisher","DOI":"10.1177\/0269216318812633"},{"key":"2026090204552123000_14.3.e013788.240","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/abm\/kay077","article-title":"Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"53","author":"Hoerger","year":"2019","journal-title":"Ann Behav Med"},{"key":"2026090204552123000_14.3.e013788.241","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011168","article-title":"Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment","volume":"13","author":"Candido","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026090204552123000_14.3.e013788.242","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad231"},{"key":"2026090204552123000_14.3.e013788.243","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2022.06.009","article-title":"Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma","volume":"82","author":"Bedke","year":"2022","journal-title":"Eur Urol"},{"key":"2026090204552123000_14.3.e013788.244","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2024.42.4_suppl.384","article-title":"Health-related quality of life (HRQoL) profile and clinical outcomes in first-line (1L) advanced renal cell carcinoma (aRCC): A modelling analysis based on CheckMate 9ER (CM9ER) trial","volume":"42","author":"Bedke","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026090204552123000_14.3.e013788.245","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1200\/JCO.2023.41.16_suppl.4527","article-title":"Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial","volume":"41","author":"Cella","year":"2023","journal-title":"JCO"},{"key":"2026090204552123000_14.3.e013788.246","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","article-title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026090204552123000_14.3.e013788.247","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026090204552123000_14.3.e013788.248","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2025.43.16_suppl.4505","article-title":"Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:56:03Z","timestamp":1788350163000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":248,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-013788"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013788","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}